Joseph Douglas Mancias

KRASG12C Inhibition Remodels the Non-Small Cell Lung Cancer Surfaceome to Uncover Targetable Vulnerabilities

This study shows that KRASG12C inhibitors alter the surface proteome of lung cancer cells, revealing FOLR1 as a new target when combined with an antibody drug conjugate.

KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

This study identifies ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer by analyzing proteomic changes induced by KRAS inhibition and developing an antibody drug conjugate.

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

This study identifies that combining DHODH inhibition with BCL-XL targeting synergistically induces apoptosis in pancreatic cancer, offering a new combination therapy strategy.

Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer

This study recharacterizes RSL3 as a broad selenoprotein inhibitor, showing its potential as a therapeutic target for colorectal cancer by inducing ferroptosis.

Autophagosomes coordinate an AKAP11-dependent regulatory checkpoint that shapes neuronal PKA signaling

This study identifies AKAP11 as a scaffold linking autophagy to PKA signaling, showing its role in phosphorylation regulation and neuronal homeostasis, with implications for schizophrenia and bipolar disorder.